The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CML/MPN 2025 | Updates in CMML: consensus guidelines, promising therapeutic approaches, & more
In this video compilation, Daniel Wiseman, MBBS, PhD, University of Manchester, Manchester, UK, provides valuable insights into updates and developments in the field of chronic myelomonocytic leukemia (CMML). Topics covered by Dr Wiseman include updates to the consensus guidelines for diagnosis and treatment of CMML, the management of CMML in the UK, and the most promising therapeutic approaches being investigated for this disease. Dr Wiseman also discusses some of his work aimed at improving the understanding of blast-phase CMML and the impact of TP53 expression. This interview took place at the European School of Haematology (ESH) 4th “How to Diagnose and Treat: CML/MPN” meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
